Mithridate to present at the 12th European Stroke Organisation Conference
Our CEO, Stephan Peters, will present Mithridate’s nanobody® based DOAC reversal asset at the innovation session of the 12th European Stroke Organisation Conference in Maastricht (May-6-8, 2026).
